IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2714
+0.0084 (3.19%)
At close: Apr 1, 2026, 4:00 PM EDT
0.2786
+0.0072 (2.65%)
Pre-market: Apr 2, 2026, 4:46 AM EDT
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
26.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% | 70 | 0 |
| Mar 31, 2024 | 67 | 6 | 9.84% | 67 | 0 |
| Mar 31, 2023 | 61 | 9 | 17.31% | 61 | 0 |
| Mar 31, 2022 | 52 | 2 | 4.00% | 52 | 0 |
| Mar 31, 2021 | 50 | 0 | - | 50 | 0 |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences | 34 |
| Boundless Bio | 28 |
| Jasper Therapeutics | 27 |
| Passage Bio | 24 |
| Daré Bioscience | 23 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| Serina Therapeutics | 13 |
IGC News
- 2 days ago - IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness - Accesswire
- 13 days ago - IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Accesswire
- 14 days ago - IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 - Accesswire
- 4 weeks ago - IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Accesswire
- 5 weeks ago - IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - Accesswire
- 5 weeks ago - IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Accesswire
- 6 weeks ago - IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - Accesswire
- 6 weeks ago - IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Accesswire